Zentalis Pharmaceuticals (ZNTL) Equity Average (2022 - 2025)
Historic Equity Average for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $263.7 million.
- Zentalis Pharmaceuticals' Equity Average fell 2843.53% to $263.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.7 million, marking a year-over-year decrease of 2843.53%. This contributed to the annual value of $387.3 million for FY2024, which is 1111.27% down from last year.
- As of Q3 2025, Zentalis Pharmaceuticals' Equity Average stood at $263.7 million, which was down 2843.53% from $284.9 million recorded in Q2 2025.
- In the past 5 years, Zentalis Pharmaceuticals' Equity Average registered a high of $502.6 million during Q3 2023, and its lowest value of $263.7 million during Q3 2025.
- Over the past 4 years, Zentalis Pharmaceuticals' median Equity Average value was $415.3 million (recorded in 2023), while the average stood at $396.5 million.
- Per our database at Business Quant, Zentalis Pharmaceuticals' Equity Average skyrocketed by 1527.71% in 2023 and then crashed by 3226.65% in 2025.
- Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Equity Average stood at $431.4 million in 2022, then grew by 6.55% to $459.6 million in 2023, then decreased by 24.78% to $345.8 million in 2024, then decreased by 23.74% to $263.7 million in 2025.
- Its Equity Average was $263.7 million in Q3 2025, compared to $284.9 million in Q2 2025 and $316.3 million in Q1 2025.